PARIS, France — June 14, 2026 — The Food and Drug Administration (FDA) on Friday granted accelerated approval to Sanofi’s Tzield for children ages 8 to 17 who have recently been diagnosed with stage 3 type 1 diabetes, opening the therapy to its largest patient population yet and significantly expanding the commercial opportunity for one of the company’s most closely watched products.

The decision marks the first time a drug has been approved in the United States to help preserve the body’s remaining insulin production in children who already have stage 3 disease. While Tzield does not cure diabetes or eliminate the need for insulin injections, it is designed to slow the autoimmune attack that destroys insulin-producing cells in the pancreas, potentially giving newly diagnosed children more stable blood sugar levels during the critical early months following diagnosis.

For Sanofi, the approval represents another step in turning its $2.9 billion acquisition of Provention Bio in 2023 into a major growth driver. Every expansion of Tzield’s approved uses increases the number of patients eligible for treatment and broadens the potential market for a therapy that carries a list price of approximately $194,000 per course.

Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys beta cells in the pancreas, preventing the body from producing sufficient insulin. By the time patients reach stage 3 disease, enough of those cells have been lost to cause dangerous blood sugar elevations and symptoms including extreme thirst, frequent urination, sudden weight loss, fatigue, and blurred vision.

From that point forward, patients typically require lifelong insulin therapy.

Tzield works differently from traditional diabetes treatments. Rather than replacing insulin, the drug targets the immune system itself. Administered through a series of intravenous infusions, it slows the immune attack responsible for destroying the remaining insulin-producing cells.

The FDA’s decision was based primarily on data from the Phase 3 PROTECT study, which enrolled 328 children and adolescents diagnosed with type 1 diabetes within the previous six weeks. Participants receiving Tzield maintained significantly greater natural insulin production compared with those receiving a placebo, suggesting the therapy can preserve pancreatic function longer after diagnosis.

Doctors have long viewed preservation of insulin production as a meaningful goal because even small amounts of natural insulin can help improve blood-sugar management and reduce the risk of severe highs and lows.

The treatment is not without risks.

According to Sanofi, the most common side effects observed in clinical trials included decreased white blood cell counts, vomiting, rash, headache, and temporary immune-system reactions. The therapy also carries warnings regarding cytokine release syndrome, a potentially serious inflammatory response, as well as the possible reactivation of dormant viral infections.

Despite those risks, diabetes specialists have increasingly viewed Tzield as one of the most significant advances in type 1 diabetes treatment in decades because it addresses the disease process itself rather than simply managing symptoms.

The business debate surrounding Tzield has largely centered on price.

The drug’s list price of roughly $194,000 for a complete treatment course drew attention from insurers and healthcare analysts when it first launched. At the time, some Wall Street analysts had projected pricing closer to $70,000 to $115,000, leading to concerns that insurance companies could push back on coverage.

As a result, access to the treatment often depends on prior authorization and case-by-case review by insurers.

Sanofi has sought to address affordability concerns through its COMPASS patient-support program, which offers copay assistance and support services designed to help eligible patients obtain coverage. Even so, healthcare experts expect reimbursement decisions by commercial insurers and government payers to remain a major factor in determining how widely the treatment is adopted.

The latest approval follows a series of regulatory wins for the therapy.

Tzield first received FDA approval in November 2022 for delaying the onset of stage 3 type 1 diabetes in individuals with stage 2 disease. In April 2026, regulators expanded that indication to include children as young as 1 year old.

Friday’s approval opens an entirely new category by allowing treatment after stage 3 diagnosis, a substantially larger population than the preventive-use market.

According to Sanofi, approximately 64,000 people are diagnosed with type 1 diabetes each year in the United States, creating a significant opportunity if physicians and insurers broadly embrace the treatment.

The approval was granted through the FDA’s accelerated approval pathway, which allows therapies for serious diseases to reach patients sooner based on surrogate measures that are reasonably likely to predict clinical benefit. In this case, preserved insulin production served as the key marker supporting approval.

Sanofi is currently conducting a confirmatory trial known as BETA-PRESERVE to verify the long-term benefits of the therapy. Failure to demonstrate those benefits could result in the FDA revisiting the approval in the future.

Sanofi (NASDAQ: SNY) shares closed at $44.25 on Thursday, June 11, little changed ahead of the announcement as investors weighed the potential impact of the latest regulatory expansion.

JBizNews Desk — Health Care

© JBizNews.com All Rights Reserved. Reproduction or distribution without written permission is prohibited.